News

Roche's Q1 Sales Increase Y/Y on Solid Performance of Key Drugs
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
As FDA delays Novavax' COVID vaccine approval, patients fight back
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might ...
pharmaphorum2d
Shifting paradigms of clinical trial design accelerate CNS R&D
Buoyed by the breakthrough technologies and methodologies that have enabled earlier intervention, Alzheimer’s drug developers ...
Novo: On Track To The Mid $40s While Loosing Market Share To Eli Lilly
Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...
Le Lézard3d
Luminopia Announces FDA Clearance for Patients with Amblyopia Aged 8 to 12 Years
Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, today announced that the U.S. Food & Drug Administration (FDA) cleared its amblyopia ...
PharmExec3d
FDA Updates Prescribing Information for Bristol Myers Squibb’s Camzyos to Reduce Echocardiography Monitoring Requirements
The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and ...
Down 61%, Is Novo Nordisk Stock Worth Buying on the Dip?
Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...
Alabama Public Radio6d
How FDA cuts could make the food and drug supply less safe
A March 11 email to FDA staff says the administration lowered government employee credit card limits to $1. Now to book ...